GRAIL (NASDAQ:GRAL) Shares Gap Down - Here's Why

Key Points

• GRAIL shares fell sharply, opening at $119.50 versus the prior close of $143.66 and trading last at $127.39, after declining revenue expectations raised concerns about commercial adoption.
• Third-quarter revenue of $37.53 million missed analysts’ $44.21 million estimate, although the $2.21 per-share loss was narrower than expected. Galleri test volume rose about 24% year over year to more than 56,000.
• An FDA advisory committee voted in favor of approving Galleri, but the FDA’s final decision is pending and expected in early 2027. GRAIL is lowering test prices to encourage adoption, which could also pressure revenue growth and margins.

GRAIL, Inc. (NASDAQ:GRAL - Get Free Report)'s stock price gapped down before the market opened on Thursday. The stock had previously closed at $143.66, but opened at $119.50. GRAIL shares last traded at $127.3850, with a volume of 234,323 shares traded.

Key GRAIL News

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: The FDA advisory committee voted in favor of approval of GRAIL’s Galleri multi-cancer early-detection test. The FDA decision is still pending, with an expected decision in early 2027. GRAIL Q3 results
• Positive Sentiment: Galleri test volume increased about 24% year over year to more than 56,000 in Q3, while revenue grew 14% to $37.3 million. GRAIL Q3 results
• Positive Sentiment: GRAIL’s quarterly loss of $2.21 per share was narrower than analysts’ expected loss of $2.45. GRAIL earnings results
• Negative Sentiment: Revenue of about $37.5 million fell short of the roughly $44.2 million analyst consensus. The miss raises concerns about the pace of commercial adoption, even as test volumes grow. GRAIL misses sales expectations
• Negative Sentiment: GRAIL is reducing Galleri prices to encourage adoption ahead of the FDA decision. The lower pricing may support test demand, but could weigh on revenue growth and margins. GRAIL earnings call pricing outlook

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on GRAL shares. UBS Group upped their price target on shares of GRAIL from $105.00 to $175.00 and gave the stock a "buy" rating in a report on Friday, October 2nd. Wall Street Zen raised shares of GRAIL from a "sell" rating to a "hold" rating in a research report on Sunday, September 13th. Morgan Stanley boosted their price objective on shares of GRAIL from $60.00 to $120.00 and gave the company an "equal weight" rating in a research report on Monday, October 12th. Royal Bank Of Canada started coverage on shares of GRAIL in a research note on Thursday, September 17th. They issued a "sector perform" rating and a $84.00 target price on the stock. Finally, TD Cowen raised their target price on shares of GRAIL from $88.00 to $180.00 and gave the stock a "buy" rating in a research report on Tuesday, October 13th. Five investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $119.80.

GRAIL Stock Down 16.9%

The company's 50 day moving average price is $115.58 and its 200 day moving average price is $79.12. The firm has a market capitalization of $5.33 billion, a price-to-earnings ratio of -12.24 and a beta of 2.86.

GRAIL (NASDAQ:GRAL - Get Free Report) last issued its earnings results on Wednesday, November 4th. The company reported ($2.21) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.45) by $0.24. The company had revenue of $37.53 million during the quarter, compared to analyst estimates of $44.21 million. GRAIL had a negative return on equity of 15.88% and a negative net margin of 236.95%. As a group, analysts expect that GRAIL, Inc. will post -10.07 earnings per share for the current year.

Insiders Place Their Bets

In other GRAIL news, CEO Joshua Ofman sold 61,452 shares of GRAIL stock in a transaction that occurred on Monday, September 21st. The shares were sold at an average price of $97.74, for a total transaction of $6,006,318.48. Following the completion of the sale, the chief executive officer directly owned 362,271 shares in the company, valued at approximately $35,408,367.54. The trade was a 14.50% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Freidin sold 23,619 shares of the company's stock in a transaction on Monday, October 5th. The shares were sold at an average price of $146.39, for a total transaction of $3,457,585.41. Following the completion of the sale, the chief financial officer directly owned 225,364 shares in the company, valued at $32,991,035.96. This trade represents a 9.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 129,944 shares of company stock valued at $14,832,805. 1.83% of the stock is owned by insiders.

Institutional Investors Weigh In On GRAIL

Hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. lifted its holdings in GRAIL by 20.5% during the 2nd quarter. BlackRock Inc. now owns 3,577,075 shares of the company's stock worth $244,207,000 after buying an additional 608,539 shares in the last quarter. State Street Corp boosted its position in shares of GRAIL by 26.1% during the 2nd quarter. State Street Corp now owns 2,385,514 shares of the company's stock worth $162,859,000 after acquiring an additional 493,621 shares in the last quarter. Primecap Management Co. CA acquired a new stake in GRAIL during the second quarter worth approximately $148,836,000. Bank of America Corp DE purchased a new stake in GRAIL in the second quarter valued at $49,389,000. Finally, Slow Capital Inc. grew its stake in GRAIL by 0.5% during the 3rd quarter. Slow Capital Inc. now owns 218,363 shares of the company's stock worth $30,597,000 after buying an additional 1,101 shares during the last quarter.

About GRAIL

GRAIL, Inc NASDAQ: GRAL is a healthcare company focused on developing blood-based screening technologies for the early detection of cancer. Its principal product is Galleri, a multi-cancer early detection test designed to identify DNA patterns associated with multiple types of cancer from a single blood sample.

Galleri is intended for use alongside recommended cancer screenings and is available by prescription through qualified healthcare providers in the United States. The test is offered as a laboratory-developed test and has not been approved or cleared by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.